Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Nov 12
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.
ABSTRACT
. . , .
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (July 30, 2025)
While osimertinib has shown meaningful activity in the most prevalent atypical mutations G719X, L861Q, and S768I, its efficacy is not uniform across all atypical mutations: L8...